CD8A and neoplasm: Additionally, TAMs can limit the efficacy of anti–PD-1/PD-L1 therapy (18, 19), as targeting TAMs synergizes with anti–PD-1/PD-L1 antibodies to reactivate CD8+ T cells and achieve more potent tumor control (11, 17).